A comparison of the guidelines for pancreatic cancer in Japan and the United States

Abstract

In this article, the Clinical Practice Guidelines for Pancreatic Cancer 2019 from the Japan Pancreas Society and the NCCN guidelines version 2. 2021 are compared and a variety of differences clarified including development methods and recommendations. The evidence on which a guideline is based is generally universal, but the guideline itself can vary from country to country, because of different social environments regarding healthcare policies and systems, and because the strength of the evidence can vary depending on where the evidence originated and where the evidence is adapted to. Optimal recommendations for patients and medical practitioners in this country should be proposed.